Trials / Terminated
TerminatedNCT03430531
Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache
Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache; A Pilot Study
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Milton S. Hershey Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to determine the effectiveness of Spheno-Palatine (SP) ganglion block to alleviate the pain of post-dural puncture headache (PDPH).
Detailed description
The primary objectives of the study are to study the effectiveness of SP ganglion block in relieving post-dural puncture headache in terms of : 1. Number of subjects who get relief of pain 2. The onset time to pain relief after application of block 3. The duration of pain relief 4. The incidence of recurrence of post-dural puncture headache Secondary objectives are to: 1. Monitor any complications due to SP ganglion block 2. Measure patient satisfaction 3. Monitor any residual effects at 1 months after the SP block
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lidocaine | Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes. |
Timeline
- Start date
- 2019-05-31
- Primary completion
- 2020-01-16
- Completion
- 2022-03-11
- First posted
- 2018-02-13
- Last updated
- 2022-06-15
- Results posted
- 2022-06-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03430531. Inclusion in this directory is not an endorsement.